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Abstract Blastic plasmacytoid dendritic cell neoplasm
(BPDCN) is a distinct and rare neoplastic entity and was
classified as a subgroup of acute myeloblastic leukemia by
the WHO in 2008. The median survival of patients was
15.2 months in a large case series. Allogeneic or autolo-
gous bone marrow transplantation has been recommended
by some reports because of the disease’s poor prognosis.
We present three patients who presented with both skin and
bone marrow infiltration. A 57-year-old man, a 62-year-old
woman, a 64-year-old man were admitted to our outpatient
clinic because of skin lesions. All of the patient’s had bone
marrow infiltration with positivity of the CD4, CD56, and
CD123 staining. Survival of the patient’s were 42, 6 and
12 months, respectively. Two of the patients who presented
as blastic form didn’t respond to any chemotherapy.
BPDCN is a difficult disease to diagnosis and manage.
CD4, CD56, CD123, CD303, and T cell leukemia/
lymphoma 1. Cutaneous lesions can present as isolated
nodules, macules, and disseminated macules and nodules.
Positivities are crucial to the diagnosis of the disease in
histological examination. Bone marrow infiltration or dis-
ease relapse at presentation were related to poor prognosis.
Complete immunocytochemical staining must be per-
formed for all patients who have cutaneous lesions with or
without blood count abnormalities. Bone marrow (alloge-
neic or autologous) transplantation should be considered at
the first remission.
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Introduction
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a
distinct and rare neoplastic entity and was classified as a
subgroup of acute myeloid leukemia by the WHO in 2008
[1]. BPDCN originates from precursors of plasmacytoid
dendritic cells. In pathological examination, the neoplastic
cells express typical CD4, CD56, and CD123 [2]. BPDCNs
usually present in an elderly patient group (60–70 years)
with male predominancy [3]. The median survival of
patients was 15.2 months in a large case series [4]. Allo-
geneic or autologous bone marrow transplantation has been
recommended by some reports because of the disease’s
poor prognosis [3, 5]. BPDCN usually presents with cuta-
neous and non-cutaneous involvement. According to the
Ann-Arbor staging system, stage IV disease is seen in
66 % of cases, and cutaneous lesions are seen in most
patients at disease onset [6]. Skin lesions may be in ma-
culopapular, nodule, or plaque form. Non-cutaneous
involvement can cause leukemic infiltration of the bone
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marrow or enlargement of the lymph nodes [6–8]. We
present three patients who presented with both skin and
bone marrow infiltration.
Case 1 Presentation
A 57-year-old man presented to our hematology outpatient
clinic in December 2010 with multiple erythematous, well
demarcated plaques and nodules on his body. There were a
few violeceous small nodules on some of the plaques
(Fig. 1a). There were also bruise-like and slightly ery-
thematous plaques on the patient’s back (Fig. 1b) and other
areas of his body (Fig. 1c). He had no prior medical history
and did not take medications. The lesions appeared about
1 month before diagnosis. The pathological examination of
the skin biopsy showed that a patchy infiltration was con-
centrated in the lower half of the dermis. In the immuno-
histochemical staining, the CD4, CD56, CD68 and CD123
were positive and the Ki-67 proliferation index was 60 %
and the CD68-PGM1, CD1a, S-100, CD138, CD25 were
negative. He had no other symptoms. There were no sig-
nificant abnormalities in the biochemical values, except for
an elevated lactate dehydrogenase (LDH) level of 566 U/L.
The bone marrow biopsy showed a 6 % neoplastic cell
infiltration which was same immunophenotypic and mor-
phologic properties with the skin lesions. There was not
lymph node enlargement in computerized tomography
scanning. Hyper-CVAD chemotherapy (CT) protocol was
applied. His skin lesions improved after 1 course of CT,
and bone marrow infiltration disappeared after 2 courses of
CT. He was released and received no further CT in March
2011. In February 2014, the patient was again admitted to
the hematology clinic because of severe weakness, pallor,
and dyspnea without skin lesions. His laboratory values
were Hemoglobine (Hb) 9.03 g/dL, white blood cells
(WBC) 35,000/mm [3], platelet (PLT) 116,000/mm [3],
and PNL (polymorph nucleated leucocytes) 3,500/mm [3].
In addition, 80 % of the cells were blastic in the peripheral
blood and diffuse blastic infiltration of the bone marrow. A
conventional karyotypic analysis of the bone marrow
revealed monosomy 5q-. He was determined to have a
leukemic form of BPDCN. After 1 course of hyper-CVAD
and high-dose methotrexate and cytarabine, the patient’s
laboratory findings did not improve and he was accepted as
refractory. Unrelated donor screening was started because
he had no siblings. We applied fludarabine–cytarabine–
granulocyte colony stimulating factor (FLAG CT) proto-
col. He was refractory to the FLAG CT and take
hydroxyurea only. The patient rejected any other CT or
transplantation. He died 2 months after the last CT. He
survived 42 months but he survived 5 months after leu-
kemic for of the BPDCN.
Case 2 Presentation
A 62-year-old woman was referred to our hematology
outpatient clinic in June 2013. She had hyperleukocytosis
and multiple skin lesions on her head and extremities
(Fig. 2). She had multiple asymptomatic skin-colored and
erythematous papules and nodules on the front of the head
skin (Fig. 2a). The patient also had multiple discrete ery-
thematous papules and nodules on her extremities
(Fig. 2b). Her laboratory values were Hb 10.3 g/dL, WBC
18,000/mm [3], PLT 35,900/mm [3], PNL 20 %, Monocyte
15 %, lymphocyte 20 and 45 % of the cells were blastic in
the peripheral blood and diffuse blastic cell infiltration of
the bone marrow. A bone marrow biopsy and skin biopsies
were done and showed diffuse neoplastic cell infiltration.
Immunohistochemical staining of the biopsy materials
showed CD34, TdT, CD117, CD8, CD10, and myeloper-
oxidase (MPO) negativity and CD4, CD56, CD123, and
CD68 positivity (Fig. 3a, b). She was diagnosed by our
department of pathology as BPDCN. The karyotypic ana-
lysis of the bone marrow was normal. We administered
AML-like regimens. Her disease (skin lesions and labora-
tory values) did not improve with 4 courses of azacitidine,
Fig. 1 Case 1 Cutaneous lesions; a multiple erythematous, well
demarcated plaques and nodules and a few violeceous small nodules
on some plaques; b bruise-like and slightly erythematous plaques on
the back
Fig. 2 Case 2 Cutaneous lesions. a Skin-colored and erythematous
papules and nodules on the frontal skin; b multiple discrete
erythematous papules and nodules on the extremities
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1 course of cytarabine (100 mg/m2/day for 7 days), ida-
rubicin (12 mg/m2/day for 3 days) CT protocol, and 1
course FLAG CT protocol, respectively. She was accepted
as refractory after these treatments. The patient died
2 months later from pulmonary sepsis after the last CT. She
survived only 6 months following diagnosis.
Case 3 Presentation
A 64-year-old man was admitted to our outpatient clinic
because of skin lesions. The condition began as a small
nodule on his back 9 months prior to his admission to the
clinic and was treated with topical clobetasol 17-propionate
ointment with some improvement. Later, the patient expe-
rienced disease progression with the development of multi-
ple new lesions. A dermatological examination revealed
8 9 5 cm, slightly indurated erythematous–violeceous pla-
ques on his scalp (Fig. 4a), as well as multiple erythematous
patches and indurated plaques involving his trunk (Fig. 4b).
A conjunctival hematoma was located on the temporal side
of his left eye (Fig. 4c). A violaceous plaque was located on
his upper gingiva (Fig. 4d) and an edematous violaceous
plaque was on the soft palate (Fig. 4e).
Skin biopsies were taken from the lesion and a bone
marrow biopsy was done. CD4, CD56, and CD123 were
positive, and CD3, CD5, CD7, CD8, CD34, CD117, pax5,
and TdT were negative by immunohistochemical staining
in both the skin and bone marrow. Complete blood count
and liver and renal function tests were normal. He did not
have organomegaly or lymph node enlargement. The
karyotypic analysis of the bone marrow was normal. Based
on the histocytochemical features of the biopsies, he was
accepted as BPDCN, and hyper-CVAD CT protocol was
started. After 1 course of CT, his skin lesions almost
improved. He has full-matched HLA sibling and we are
planning allogeneic bone marrow transplantation at first
remission for him.
Discussion
BPDCN is a difficult disease to diagnosis and manage [9].
While neoplastic cells infiltrate the dermis at disease onset,
neoplastic cell infiltration spreads to perivascular areas as
the disease progresses [2]. Neoplastic cells infiltrated the
dermis layer in our three patients. The expected patho-
logical findings of BPDCN are characterized by diffuse,
Fig. 3 Case 2 Pathological findings. a The cytomorphology of the immature tumor cells in blastic plasmacytoid dendritic cell neoplasm shows
medium-size immature cells with variable amounts of cytoplasm (H?E, 950) b CD68 strongly expressed (Immunoperoxidase, 9200)
Fig. 4 Cutaneous lesions in Case 3. a Slightly indurated, erythem-
atous–violaceous plaque on the scalp; b multiple erythematous
patches and indurated plaques on the trunk; c conjunctival hematoma
located on the temporal side; d violeceous plaque located on the upper
gingiva; e edematous violeceous plaque on the soft palate
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monotonous infiltration of the dermis by medium-sized
cells with round nuclei [8]. CD4, CD56, CD123, CD303,
and T cell leukemia/lymphoma 1 (TCL1) positivities are
crucial to the diagnosis of the disease in histological
examination [4, 10]. Julia et al. reported that only 50 % of
cases had positivities in all five markers [4]. CD4?/CD56?
co-expression is important in the diagnosis of BPDCN, as
well [4]. In the same study, Julia et al. detected that 99 %
of patients were positive in CD4, CD56, CD123, CD303,
and TCL1 in histochemical staining (98, 92, 97,63, 99 %,
respectively) [4]. CD56 and CD123 were positive in the
bone marrow biopsies of our three patients; however, we
lacked laboratory resources to examine other markers.
Cutaneous lesions with typically immunohistochemical
staining helped us to establish exact diagnoses.
The bone marrow conventional cytogenetic chromo-
some analyse of three of our patients were initially normal.
When the first patient relapsed, monosomy 5q- cytoge-
netic abnormality was seen as leukemic presentation.
Chromosome abnormalities are frequently encountered in
BPDCNs. The most common are 5q (72 %), 12p and 13q
(64 %), 6q (50 %), 15q (43 %), and monosomy 9 (28 %),
as in our first patient [11].
According to a recently published large case series,
cutaneous lesions can present as isolated nodules, macules,
and disseminated macules and nodules. Purplish nodules
were the most common lesions (73 %) in the patients
diagnosed with BPDCN [12]. Our patients cutaneous lesions
were usually plaques, nodules, and papules. The third
patient’s lesions were localized atypically. However we
didn’t reveal any biopsy from gingival lesions, the lesions
disappear after CT. To the best of our knowledge, there are
no case reports in the literature about presentations of
BPDCN in the gingiva, soft palatum, and conjunctiva.
The application of multi-agent CT protocols is recom-
mended; however, the effective application of this treatment is
not usually possible due to the patients’ older ages [2, 13].
Chemotherapy protocols for acute lymphoblastic leukemia
have slightly longer survival than CT protocols for acute
myeloid leukemia [6]. The complete remission rate was 90 %
with hyper-CVAD CT protocol [14], as in our two patients
who did not present in the leukemic phase. Gruson et al.
reported that L-asparaginase–methotrexate and dexametha-
sone combination therapy can be an alternative treatment
strategy with good tolerability and high efficacy for older and
otherwise unfit patients [15]. Despite the high response rates to
the multi-agent CT protocols, remission duration is still lim-
ited in BPDCN [16]. Bone marrow infiltration or disease
relapse at presentation were related to poor prognosis as did
our first and second patients. Patients who have isolated
cutaneous lesions tend to survive longer [6]. However, in
another study of 33 patients, bone marrow infiltration did not
affect the prognosis [17]. Weil et al. reported that allogeneic
bone marrow transplantation in first remission was related to
3-years longer progression-free survival and overall survival
(33 and 41 %respectively) [5]. A patient who underwent
reduced intensity transplantation had a 4-year survival [16]. In
another recent report, autologous hematopoietic stem cell
transplantation was a good option for patients with BPDCN
without available donors [3].
Our patients were elderly, making it difficult to admin-
ister multi-agent CT protocols. A high number of infectious
complications were seen in all three. None of the patient
underwent allogeneic transplantation. Case 1 rejected any
additional therapy, Case 2 had no response to any CT
protocol, including FLAG, and transplantation planning for
case 3 after completion of remition induction CT protocol.
Conclusion
We share our three patients which have BPDCN here.
BPDCN is a rare disease that is difficult for pathologists to
diagnose and for clinicians to manage. Complete immuno-
cytochemical staining must be performed for all patients who
have unexplained, atypical cutaneous lesions with or without
blood count abnormalities. Bone marrow infiltration of
BPDCN is related to very short overall survival and to lower
response rates. Bone marrow (allogeneic or autologous)
transplantation should be considered at the first remission.
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